Among the known actionable alterations, both IDH1 mutations and FGFR2 aberrations have been associated with an immune-suppressive TIME [82] and studies are ongoing to establish if the addition of an anti-PD-(L)1 agent to the IDH1 inhibitor ivosidenib (NCT06501625, NCT05921760) and the FGFR2 inhibitor pemigatinib (NCT06530823) could revert this effect and improve outcomes in refractory CCA. This evidence concerns the gene IDH1 and cholangiocarcinoma.